THAP3

Across TCGA pan-cancer cohorts, THAP3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated THAP3 data layer compared with 18 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher THAP3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated THAP3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, GBM, and LUAD are the cancer types where THAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.970	0.603	.003	40	view →
GBM	DFS	Quartile	All	0.568	0.927	.025	3	view →
LUAD	OS	Median	II,III,IV	0.822	0.299	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

THAP3–HNSC (DFS)

Open the HNSC breakdown →